APhase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced SolidTumors

@inproceedings{Steele2008APhase1P,
  title={APhase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced SolidTumors},
  author={Nicola L. Steele and JaneA. Plumb and LauraVidal and JetteTj rnelund and Poul Knoblauch and Annie Rasmussen and Chean Eng Ooi and Peter Buhl-Jensen and R. Brown and T. R. Jeffry Evans and S. DeBono},
  year={2008}
}
  • Nicola L. Steele, JaneA. Plumb, +8 authors S. DeBono
  • Published 2008
Purpose:To determine the safety, dose-limiting toxicity, maximum tolerated dose, and pharmacokinetic and pharmacodynamic profiles of the novel hydroxamate histone deacetylase inhibitor belinostat (previously named PXD101) in patients with advanced refractory solid tumors. Experimental Design: Sequential dose-escalating cohorts of three to six patients received belinostat administered as a 30-min i.v. infusion on days1to 5 of a 21-day cycle. Pharmacokinetic variables were evaluated at all dose… CONTINUE READING